Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Extension Study for Patients with Early Alzheimer's Disease Enrolled in ANAVEX2-73-AD-004
2021-004325-80Phase 2Completed
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Oct 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blarcamesine in Alzheimer's disease (AD), sponsored by Anavex Life Sciences Corp. Started Oct 2021; status: completed.
02
Drugs
blarcamesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2021-004325-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004325-80.